IN8BIO INC. - COMMON STOCK

IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

16 дек 2021 06:00:01 Источник Nasdaq GlobeNewswire

IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

09 дек 2021 15:30:00 Источник Nasdaq GlobeNewswire

IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer

16 ноя 2021 06:00:01 Источник Nasdaq GlobeNewswire

IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors

11 ноя 2021 06:00:01 Источник Nasdaq GlobeNewswire

IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

10 ноя 2021 15:15:00 Источник Nasdaq GlobeNewswire

IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO

04 ноя 2021 07:00:03 Источник Nasdaq GlobeNewswire

IN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021

04 окт 2021 15:15:00 Источник Nasdaq GlobeNewswire

IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

10 сен 2021 15:15:00 Источник Nasdaq GlobeNewswire

IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference

30 авг 2021 06:00:00 Источник Nasdaq GlobeNewswire

IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

11 авг 2021 07:00:01 Источник Nasdaq GlobeNewswire

IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors

04 авг 2021 07:00:01 Источник Nasdaq GlobeNewswire

IN8bio Announces Pricing of Initial Public Offering

30 июл 2021 06:00:00 Источник Nasdaq GlobeNewswire